[1] Weng WZ, Chen JF, Peng XH,et al. Risk factors for underlying comorbidities and complications in patients with hepatitis B virus-related acute-on-chronic liver failure. Epidemiol Infect, 2022,150(1):e147. [2] Tu B, Zhang YN, Bi JF,et al. Multivariate predictive model for asymptomatic spontaneous bacterial peritonitis in patients with liver cirrhosis. World J Gastroenterol, 2020,26(29):4316-4326. [3] Kang J, Postigo-Fernandez J, Kim K,et al. Notch-mediated hepatocyte MCP-1 secretion causes liver fibrosis. JCI Insight, 2023,8(3):e165369. [4] 陈攀丽,张炳勇,付雪琴,等. 肝硬化合并自发性细菌性腹膜炎患者血清和腹水中固有淋巴样细胞亚群的变化. 中华医学杂志,2022,102(2):141-146. [5] Liu L, Xiao N, Chen P,et al. IL-10 predicts the prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure combined with spontaneous bacterial peritonitis. Front Med (Lausanne), 2023,10(1):1188300. [6] García-Peñarrubia P, Ruiz-Alcaraz AJ, Ruiz-Ballester M,et al. Recent insights into the characteristics and role of peritoneal macrophages from ascites of cirrhotic patients. World J Gastroenterol, 2021,27(41):7014-7024. [7] 中华医学会肝病学分会. 肝硬化腹水及相关并发症的诊疗指南. 实用肝脏病杂志,2018,21(1):21-31. [8] 中华医学会肝病学分会. 肝硬化诊治指南.实用肝脏病杂志,2019,22(6):770-792. [9] 张继明,翁心华. 自发性细菌性腹膜炎的诊断及防治. 中华肝脏病杂志,2005,13(6):459-460. [10] Biggins SW, Angeli P, Garcia-Tsao G,et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American association for the study of liver diseases. Hepatology, 2021,74(2):1014-1048. [11] Marciano S, Díaz JM, Dirchwolf M, et al. Spontaneous bacterial peritonitis in patients with cirrhosis: incidence, outcomes, and treatment strategies. Hepat Med, 2019,11(1):13-22. [12] Samonakis DN, Gatselis N, Bellou A,et al. Spontaneous bacterial peritonitis: a prospective Greek multicenter study of its epidemiology, microbiology, and outcomes. Ann Gastroenterol, 2022,35(1):80-87. [13] Xu L, Sharkey D, Cantley LG. Tubular GM-CSF promotes late MCP-1/CCR2-mediated fibrosis and inflammation after ischemia/reperfusion injury. J Am Soc Nephrol, 2019,30(10):1825-1840. [14] Janssens P, Decuypere JP, De Rechter S, et al. Enhanced MCP-1 release in early autosomal dominant polycystic kidney disease. Kidney Int Rep, 2021,6(6):1687-1698. [15] Moloi MW, Rusch JA, Omar F,et al. Urinary MCP-1 and TWEAK as non-invasive markers of disease activity and treatment response in patients with lupus nephritis in South Africa. Int Urol Nephrol, 2021,53(9):1865-1873. [16] 刘玉玲,甄增国,王慧娟,等. 益生菌制剂对肝硬化并发自发性细菌性腹膜炎患者肠道屏障功能的影响. 实用肝脏病杂志,2021,24(6):867-870. [17] Queck A, Bode H, Uschner FE,et al. Systemic MCP-1 levels derive mainly from injured liver and are associated with complications in cirrhosis. Front Immunol, 2020,11(1):354. [18] 吴成勇,陈冲,刘文艳,等. 慢加急性乙型肝炎肝衰竭患者并发细菌感染及其预测模型效能评价. 实用肝脏病杂志,2023,26(1):59-62. [19] Wu X, Luo J, Huang W,et al. Role of ascitic endocan levels in the diagnosis of spontaneous bacterial peritonitis in decompensated cirrhosis. Biomarkers, 2020,25(4):360-366. [20] Qian D, Zhang Y. Influence of xuebijing injection combined with cefoperazone sodium and sulbactam sodium in treating hepatitis B-induced liver cirrhosis complicated by spontaneous bacterial peritonitis: TNF-α, IL-18, IL-6, and hepatic function. Am J Transl Res, 2021,13(4):2907-2914. [21] Wang Z, Wang A, Gong Z,et al. Plasma claudin-3 is associated with tumor necrosis factor-alpha-induced intestinal endotoxemia in liver disease. Clin Res Hepatol Gastroenterol, 2019,43(4):410-416. [22] Zhao S, Xu W, Xie YX,et al. CXCR5+CD4+ T cell subsets and their relationship to immune dysfunction in chronic hepatitis B-associated liver cirrhosis. J Gastroenterol Hepatol, 2020,35(4):689-695. [23] Chan PC, Cheung KWA, Chan CH,et al. Patterns and infection outcomes of bacterial colonization in patients with indwelling abdominal drains for malignant ascites. Ann Palliat Med, 2020,9(6):4490-4501. |